TRANSITION FROM ONGOING INFLIXIMAB REFERENCE PRODUCT TO ITS BIOSIMILAR: CAN WE TALK ABOUT A FAILURE?

被引：4

作者：

Akrout, W. ^{[1
]}

Bosycot, A. ^{[1
]}

Levet-Labry, R. ^{[1
]}

Gazaix-Fontaine, E. ^{[2
]}

Paul, M. ^{[1
]}

Claudepierre, P. ^{[2
]}

机构：

[1] Henri Mondor Univ Hosp, AP HP, Clin Pharm Dept, Creteil, France

[2] Henri Mondor Univ Hosp, AP HP, Rheumatol Dept, Creteil, France

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷

关键词：

D O I：

10.1136/annrheumdis-2017-eular.4823

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

AB0708

引用

页码：1301 / 1302

页数：2

共 3 条

[1] Biosimilar therapies in inflammatory bowel disease: should we care about patient profile? [J].

Fiorino, Gionata ;

Fazio, Maria ;

Danese, Silvio .

EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (04) :361-363

[2] Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence [J].

Jacobs, Ira ;

Petersel, Danielle ;

Isakov, Leah ;

Lula, Sadiq ;

Sewell, K. Lea .

BIODRUGS, 2016, 30 (06) :525-570

[3] Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study [J].

Park, Won ;

Yoo, Dae Hyun ;

Jaworski, Janusz ;

Brzezicki, Jan ;

Gnylorybov, Andriy ;

Kadinov, Vladimir ;

Goecke Sariego, Irmgadt ;

Abud-Mendoza, Carlos ;

Otero Escalante, William Jose ;

Kang, Seong Wook ;

Andersone, Daina ;

Blanco, Francisco ;

Hong, Seung Suh ;

Lee, Sun Hee ;

Braun, Juergen .

ARTHRITIS RESEARCH & THERAPY, 2016, 18

← 1 →